James Thomas Coates, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nimorazole | 1 | 2018 | 1 | 0.650 |
Why?
|
| Camptothecin | 1 | 2021 | 576 | 0.630 |
Why?
|
| Plethysmography | 1 | 2014 | 180 | 0.480 |
Why?
|
| Immunoconjugates | 1 | 2021 | 901 | 0.470 |
Why?
|
| Lung Volume Measurements | 1 | 2014 | 378 | 0.450 |
Why?
|
| Breath Tests | 1 | 2014 | 280 | 0.450 |
Why?
|
| Radiometry | 2 | 2015 | 800 | 0.430 |
Why?
|
| Radiation Tolerance | 1 | 2015 | 486 | 0.420 |
Why?
|
| Tumor Burden | 1 | 2018 | 1915 | 0.410 |
Why?
|
| Radiation Injuries | 2 | 2015 | 1180 | 0.360 |
Why?
|
| Lung Injury | 1 | 2014 | 436 | 0.340 |
Why?
|
| Critical Care | 1 | 2022 | 2647 | 0.340 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 1941 | 0.280 |
Why?
|
| Nitric Oxide | 1 | 2014 | 2132 | 0.260 |
Why?
|
| Models, Biological | 3 | 2017 | 9583 | 0.260 |
Why?
|
| Genomics | 4 | 2021 | 5720 | 0.220 |
Why?
|
| Prostatic Neoplasms | 2 | 2016 | 11124 | 0.210 |
Why?
|
| Retinal Neoplasms | 2 | 2013 | 144 | 0.200 |
Why?
|
| Models, Statistical | 1 | 2016 | 5102 | 0.190 |
Why?
|
| Retinoblastoma | 2 | 2013 | 318 | 0.190 |
Why?
|
| Cell Hypoxia | 3 | 2019 | 675 | 0.190 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2020 | 94 | 0.180 |
Why?
|
| Radiotherapy | 2 | 2018 | 1533 | 0.170 |
Why?
|
| Amides | 1 | 2019 | 459 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 15519 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 1 | 2021 | 1602 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2019 | 2557 | 0.120 |
Why?
|
| Exhalation | 1 | 2014 | 167 | 0.120 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 1988 | 0.110 |
Why?
|
| Conjunctival Neoplasms | 1 | 2013 | 79 | 0.110 |
Why?
|
| Finite Element Analysis | 1 | 2014 | 431 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2018 | 1147 | 0.100 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 1869 | 0.100 |
Why?
|
| Thorax | 1 | 2014 | 547 | 0.100 |
Why?
|
| Erectile Dysfunction | 1 | 2015 | 461 | 0.100 |
Why?
|
| Pressure | 1 | 2014 | 1203 | 0.100 |
Why?
|
| Rectum | 1 | 2015 | 904 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 627 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 3616 | 0.090 |
Why?
|
| Probability | 1 | 2015 | 2505 | 0.090 |
Why?
|
| Decision Making | 1 | 2022 | 3887 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 806 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 1130 | 0.080 |
Why?
|
| Corneal Diseases | 1 | 2013 | 636 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 2219 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 3703 | 0.070 |
Why?
|
| Phantoms, Imaging | 1 | 2014 | 2480 | 0.070 |
Why?
|
| Equipment Design | 1 | 2014 | 3582 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 2716 | 0.070 |
Why?
|
| Prognosis | 2 | 2018 | 29063 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 16689 | 0.060 |
Why?
|
| Lymphoma | 1 | 2013 | 1877 | 0.060 |
Why?
|
| Risk | 1 | 2015 | 9687 | 0.050 |
Why?
|
| Humans | 11 | 2022 | 744343 | 0.050 |
Why?
|
| Rats | 2 | 2019 | 24260 | 0.050 |
Why?
|
| Disease Progression | 1 | 2018 | 13284 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 9959 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2014 | 6196 | 0.050 |
Why?
|
| Genotype | 1 | 2015 | 12951 | 0.050 |
Why?
|
| Logistic Models | 1 | 2015 | 13408 | 0.040 |
Why?
|
| Atovaquone | 1 | 2019 | 58 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 14722 | 0.040 |
Why?
|
| Neoplasms | 2 | 2019 | 21683 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10481 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 19905 | 0.040 |
Why?
|
| Radiobiology | 1 | 2017 | 85 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 18029 | 0.030 |
Why?
|
| Male | 3 | 2018 | 350118 | 0.030 |
Why?
|
| Protons | 1 | 2019 | 1127 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2017 | 63114 | 0.030 |
Why?
|
| Female | 3 | 2021 | 380194 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2019 | 3689 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 35421 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 13695 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 6386 | 0.020 |
Why?
|
| Animals | 3 | 2019 | 168757 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 72290 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 77449 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4751 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5179 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 6314 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 4217 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 3505 | 0.020 |
Why?
|
| Aged | 1 | 2015 | 163280 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2013 | 13033 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 9727 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 81183 | 0.010 |
Why?
|